Health
Deactivating gene could boost immunotherapy for head and neck cancer – Drug Target Review
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
Posted: 24 March 2021 | Victoria Rees (Drug Target Review) | No comments yet
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
By targeting an enzyme that plays a key role in head and neck cancer cells, researchers were able to significantly slow the growth and spread of tumours in mice and enhance the effectiveness of an immunotherapy to which these types of cancers often become resistant. The study was conducted…
-
Noosa News22 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland
-
General21 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News21 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland
-
Noosa News20 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation